Daylight photodynamic therapy with methylene blue in plane warts: a randomized double-blind placebo-controlled study

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a randomized controlled trial.

There are no published studies of methylene blue (MB) as a photosensitizer (PS) used in DL-PDT.

Daylight exposure was not monitored with a dosimeter.

Who Took Part

The study group was 20 patients.

The age groups tagged for this paper are young children, children and teenagers.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Methylene blue (non-peptide stack partner) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Methylene blue (non-peptide stack partner), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Methylene blue (non-peptide stack partner) could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Methylene Blue, Photochemotherapy, Sunlight and Warts.

Author keywords: daylight photodynamic therapy, photosensitizer and plane warts.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Methylene blue (non-peptide stack partner) in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Photodermatology, photoimmunology & photomedicine), a journal based in England.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.